一對中國夫婦為了治療患有罕見基因突變的女兒梅（化名），聯繫了上海著名的神經科學家仇子龍，希望能透過基因療法改善她的發育遲緩問題。這對夫婦支付了八十六萬美元，讓仇子龍為梅進行這項全球首創的腦部基因療法治療。（關鍵數字：860,000）

然而，在接受這項量身定做的治療不到一週後，這位六歲的女孩便因為嚴重的免疫反應引發致命血栓而離世。《科學》雜誌與「撤稿觀察」組織的聯合調查指出，梅的家人指控仇子龍未告知治療可能導致死亡的風險，也未透露先前動物實驗中出現的安全隱患。（關鍵數字：less than a week）

這起悲劇引發了嚴重的倫理疑慮，因為這項高風險的實驗性治療被用於一種非致命性的疾病上。此外，外部機構與倫理委員會的監管不足，也對中國致力成為全球生技領導者的雄心造成打擊，凸顯了科學發展必須建立在公開、誠實和透明的基礎上。

A Chinese couple, desperate to help their daughter Mei (a pseudonym) who suffered from a rare genetic mutation causing developmental delays, contacted prominent Shanghai neuroscientist Zilong Qiu for gene therapy. For $860,000, Qiu agreed to administer this world-first, brain-directed gene therapy treatment to Mei.

Tragically, less than a week after receiving the tailored treatment, the six-year-old girl died from a fatal blood clot triggered by a severe immune reaction. A joint investigation by Science magazine and Retraction Watch revealed that Mei's family accused Qiu of failing to disclose the risk of death or the safety issues flagged during earlier animal testing.

This tragedy raises serious ethical concerns, as a highly risky experimental treatment was used for a non-fatal condition. Furthermore, the lack of adequate oversight by regulatory authorities and ethical review boards deals a blow to China's ambitions of becoming a global biotech leader, highlighting that true scientific advancement must be rooted in openness, honesty, and transparency.